ACTIV-1 IM

Study at a Glance

Estimated Time Commitment

To be discussed

Eligibility

Hospitalized with COVID, any level of oxygen support

Diagnosis Required

Confirmed COVID diagnosis

Diseases Being Studied

SARS-CoV-2
Location: San Antonio, TX

Sponsor: NIH-NCATS

Coordinating Center/CRO: Duke Clinical Research Institute (DCRI)

Primary Objective: To evaluate the clinical efficacy of different investigational therapeutics relative to the control arm in adults hospitalized with COVID-19 with respect to time to recovery by Day 29. 

Study drugs: Remdesivir + (IV Abatacept vs IV placebo x1 dose); Remdesivir +(IV Infliximab vs IV placebo x 1 dose); Remdesivir + (oral CVC vs oral placebo twice daily for 28 days)

Study Progress: as of 12/31/21 Enrollment complete —1971

Final local enrollment: 42; 4 deaths while on study, 1 death on day 62; 38 completed through Day 60

Meet Your Clinical Research Team

Contact us

Principal Investigator: Local PI: Jan Patterson, M.D., M.S., Philip Ponce, M.D., and Barbara Taylor, M.D., M.S.

For questions on this study, please contact Dr. Jan Patterson